Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neogenix Oncology, a research-driven biopharmaceutical company, has appointed Philip Arlen to its board of directors. The company has also announced that Dr Arlen had accepted the company's offer to become president and chief medical officer, effective immediately.
Subscribe to our email newsletter
Dr Arlen will initially focus on the clinical development program for the company’s novel monoclonal antibody, NPC-1C, which is intended for the treatment of pancreatic cancer. In addition, he will play an integral role in the R&D effort overseeing the translation of Neogenix Oncology’s pipeline candidates into potential clinical products.
Prior to joining Neogenix, Dr Arlen was director of the clinical research group for laboratory of tumor immunology and biology at the National Cancer Institute in Bethesda, Maryland.
Thomas Lytle, COO of Neogenix, said: “We are delighted that Dr Arlen has joined Neogenix as a key member of our leadership team. With his extensive knowledge and clinical experience, he will make a significant contribution toward guiding our development programs and helping the company to develop its portfolio of innovative cancer therapeutics and diagnostics.”